<html><head></head><body><h1>Ephedrine and Guaifenesin</h1><ul class="ddc-anchor-links"><li>Pharmacology</li>
<li>Contraindications</li>
<li>Storage</li>
<li>Interactions</li>
<li>Warnings</li>
<li>Pregnancy</li>
<li>Patient education</li></ul><h2>Pronunciation</h2><p>(e FED rin &amp; gwye FEN e sin)</p><h2>Index Terms</h2><ul><li>Guaifenesin and Ephedrine</li></ul><h2>Dosage Forms</h2><p>Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p><p>Tablet, Oral: </p><p>Bronkaid: Ephedrine sulfate 25 mg and guaifenesin 400 mg</p><p>Primatene Asthma: Ephedrine sulfate 12.5 mg and guaifenesin 200 mg [scored]</p><h2>Brand Names: U.S.</h2><ul><li>Bronkaid [OTC]</li><li>Primatene Asthma [OTC]</li></ul><h2>Pharmacologic Category</h2><ul><li>Expectorant/Decongestant</li></ul><h2 class="ddc-anchor-offset" id="pharmacology">Pharmacology</h2><p>Ephedrine: Releases tissue stores of norepinephrine and thereby produces an alpha- and beta-adrenergic stimulation; longer-acting and less potent than epinephrine</p><p>Guaifenesin: Thought to act as an expectorant by irritating the gastric mucosa and stimulating respiratory tract secretions, thereby increasing respiratory fluid volumes and decreasing mucous viscosity</p><h2 class="ddc-anchor-offset" id="contraindications">Contraindications</h2><p>OTC labeling: When used for self-medication, do not use if asthma is not confirmed by a health care provider; coadministration with a monoamine oxidase inhibitor (MAOI) or 2 weeks after discontinuing an MAOI; hypersensitivity to ephedrine, guaifenesin, or any component of the formulation.</p><h2>Administration</h2><p>Administer without regard to food.</p><h2 class="ddc-anchor-offset" id="storage">Storage</h2><p>Store at 20° to 25°C (68° to 77°F).</p><h2 class="ddc-anchor-offset" id="interactions">Drug Interactions</h2><p>Alkalinizing Agents: May increase the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting).<i> Monitor therapy</i></p><p>Alpha1-Blockers: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.<i> Monitor therapy</i></p><p>AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.<i> Monitor therapy</i></p><p>Atropine (Systemic): May enhance the therapeutic effect of EPHEDrine (Systemic).<i> Monitor therapy</i></p><p>Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.<i> Consider therapy modification</i></p><p>Bretylium: May enhance the therapeutic effect of Alpha-/Beta-Agonists (Direct-Acting).<i> Monitor therapy</i></p><p>Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<i> Monitor therapy</i></p><p>Carbonic Anhydrase Inhibitors: May increase the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting).<i> Monitor therapy</i></p><p>Cardiac Glycosides: EPHEDrine (Systemic) may enhance the arrhythmogenic effect of Cardiac Glycosides. <i> Monitor therapy</i></p><p>Chloroprocaine: May enhance the hypertensive effect of Alpha-/Beta-Agonists.<i> Monitor therapy</i></p><p>CloNIDine: May enhance the therapeutic effect of EPHEDrine (Systemic).<i> Monitor therapy</i></p><p>CloZAPine: May diminish the therapeutic effect of Alpha-/Beta-Agonists.<i> Monitor therapy</i></p><p>Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Consider therapy modification</i></p><p>DexAMETHasone (Systemic): EPHEDrine (Systemic) may decrease the serum concentration of DexAMETHasone (Systemic). <i> Monitor therapy</i></p><p>Disulfiram: May enhance the adverse/toxic effect of Products Containing Ethanol. Management: Do not use disulfiram with dosage forms that contain ethanol.<i> Avoid combination</i></p><p>Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Monitor therapy</i></p><p>Droxidopa: EPHEDrine (Systemic) may enhance the hypertensive effect of Droxidopa. <i> Monitor therapy</i></p><p>Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.<i> Avoid combination</i></p><p>FentaNYL: Alpha-/Beta-Agonists (Indirect-Acting) may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed. <i> Monitor therapy</i></p><p>Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Monitor therapy</i></p><p>Hyaluronidase: May enhance the vasoconstricting effect of Alpha-/Beta-Agonists. Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of alpha-/beta-agonists.  Use of hyaluronidase for other purposes in patients receiving alpha-/beta-agonists may be considered as clinically indicated.<i> Consider therapy modification</i></p><p>Inhalational Anesthetics: EPHEDrine (Systemic) may enhance the arrhythmogenic effect of Inhalational Anesthetics. <i> Avoid combination</i></p><p>Iobenguane Radiopharmaceutical Products: Alpha-/Beta-Agonists (Indirect-Acting) may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products.  Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose.<i> Avoid combination</i></p><p>Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.<i> Consider therapy modification</i></p><p>Methotrimeprazine: Products Containing Ethanol may enhance the adverse/toxic effect of Methotrimeprazine. Specifically, CNS depressant effects may be increased.  Management: Avoid products containing alcohol in patients treated with methotrimeprazine.<i> Avoid combination</i></p><p>Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting). While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.  Refer to linezolid specific monographs for details.<i> Avoid combination</i></p><p>Oxytocin: May enhance the hypertensive effect of EPHEDrine (Systemic).<i> Monitor therapy</i></p><p>Ozanimod: May enhance the hypertensive effect of Sympathomimetics. Management: Concomitant use of ozanimod with sympathomimetic agents is not recommended. If combined, monitor patients closely for the development of hypertension, including hypertensive crises.<i> Consider therapy modification</i></p><p>Propofol: May enhance the therapeutic effect of EPHEDrine (Systemic).<i> Monitor therapy</i></p><p>QuiNIDine: EPHEDrine (Systemic) may diminish the therapeutic effect of QuiNIDine. QuiNIDine may diminish the therapeutic effect of EPHEDrine (Systemic). <i> Monitor therapy</i></p><p>Reserpine: May diminish the therapeutic effect of Alpha-/Beta-Agonists (Indirect-Acting).<i> Monitor therapy</i></p><p>Rocuronium: EPHEDrine (Systemic) may enhance the therapeutic effect of Rocuronium. <i> Monitor therapy</i></p><p>Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists. Management: If possible, avoid coadministration of direct-acting alpha-/beta-agonists and serotonin/norepinephrine reuptake inhibitors. If coadministered, monitor for increased sympathomimetic effects (eg, increased blood pressure, chest pain, headache).<i> Consider therapy modification</i></p><p>Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. <i> Monitor therapy</i></p><p>Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.<i> Monitor therapy</i></p><p>Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Monitor therapy</i></p><p>Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Monitor therapy</i></p><p>Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha-/Beta-Agonists. Management: Avoid, if possible, the use of alpha-/beta-agonists in patients receiving tricyclic antidepressants. If combined, monitor for evidence of increased pressor effects and consider reductions in initial dosages of the alpha-/beta-agonist.<i> Consider therapy modification</i></p><p>Urinary Acidifying Agents: May decrease the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting).<i> Monitor therapy</i></p><h2>Adverse Reactions</h2><p>The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p><p>Frequency not defined. </p><p>Cardiovascular: Hypertension, tachycardia</p><p>Central nervous system: Emotional disturbance, headache, insomnia, nervousness, seizure </p><p>Hypersensitivity: Hypersensitivity reaction</p><p>Neuromuscular &amp; skeletal: Tremor</p><p>Respiratory: Cough, exacerbation of asthma, productive cough</p><h2 class="ddc-anchor-offset" id="warnings">Warnings/Precautions</h2><p><b><i>Concerns related to adverse effects:</i></b></p><p>• Cardiovascular effect: May cause hypertension or tachycardia, increasing the risk of myocardial infarction (MI) and/or stroke. Serious cardiovascular events (eg, MI, stroke, arrhythmias), including deaths, have been previously reported with use of dietary supplements containing ephedra alkaloids (Haller, 2000).</p><p><b><i>Disease-related concerns:</i></b></p><p>• Asthma: Only use with a diagnosis of asthma; notify health care provider if asthma becomes worse during use. Inhaled bronchodilators provide more rapid symptomatic relief of asthma than ephedrine/guaifenesin.</p><p>• Cardiovascular disease: Use with caution in patients with heart disease and/or hypertension.</p><p>• Diabetes: Use with caution in patients with diabetes mellitus.</p><p>• Glaucoma: Use with caution in patients with narrow angle glaucoma.</p><p>• Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.</p><p>• Psychiatric conditions: Use with caution in patients with psychiatric or emotional conditions.</p><p>• Seizures: Use with caution in patients with a history of seizure disorder.</p><p>• Thyroid disease: Use with caution in patients with thyroid disease.</p><p><b><i>Special populations:</i></b></p><p>• Pediatric: Not for OTC use in children &lt;12 years.</p><h2 class="ddc-anchor-offset" id="pregnancy">Pregnancy Considerations</h2><p>Refer to individual monographs.</p><h2 class="ddc-anchor-offset" id="patient-education">Patient Education</h2><p><b>What is this drug used for?</b></p><p>• It is used to treat asthma.</p><p>• It is used to thin mucus so it can be taken from the body by coughing.</p><p><b>All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:</b></p><p>• Trouble sleeping</p><p>• Tremors</p><p><b>WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:</b></p><p>• Severe headache</p><p>• Severe dizziness</p><p>• Passing out</p><p>• Vision changes</p><p>• Chest pain</p><p>• Weakness on 1 side of the body, trouble speaking or thinking, change in balance, drooping on one side of the face, or blurred eyesight</p><p>• Fast heartbeat</p><p>• Seizures</p><p>• Severe anxiety</p><p>• Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.</p><p><b>Note:</b> This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.</p><p><b>Consumer Information Use and Disclaimer:</b> This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a limited summary of general information about the medicine's uses from the patient education leaflet and is not intended to be comprehensive. This limited summary does NOT include all information available about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not intended to provide medical advice, diagnosis or treatment and does not replace information you receive from the healthcare provider. For a more detailed summary of information about the risks and benefits of using this medicine, please speak with your healthcare provider and review the entire patient education leaflet.</p><h2>More about ephedrine / guaifenesin</h2><ul class="more-resources-list more-resources-list-general">
<li>Side Effects</li>
<li>Imprints, Shape &amp; Color Data</li>
<li>Drug Interactions</li>
<li>18 Reviews</li>
<li>Drug class: upper respiratory combinations</li>
<li>FDA Alerts (1)</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Cold Symptoms</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p></body></html>